Discovery of Clinical Candidate GLPG3970: A Potent and Selective Dual SIK2/SIK3 Inhibitor for the Treatment of Autoimmune and Inflammatory Diseases-Reference-Cited by-同舟云学术

Discovery of Clinical Candidate GLPG3970: A Potent and Selective Dual SIK2/SIK3 Inhibitor for the Treatment of Autoimmune and Inflammatory Diseases

Published:2024-03-29 Issue:7 Volume:67 Page:5233-5258
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Peixoto Christophe¹,Joncour Agnes¹,Temal-Laib Taouès¹,Tirera Amynata¹,Dos Santos Aurélie¹,Jary Hélène¹,Bucher Denis¹,Laenen Wendy²,Pereira Fernandes Anna²,Lavazais Stephanie¹,Delachaume Carole¹,Merciris Didier¹,Saccomani Corinne¹,Drennan Michael²,López-Ramos Miriam¹,Wakselman Emanuelle¹,Dupont Sonia¹,Borgonovi Monica¹,Roca Magadan Carlos¹,Monjardet Alain¹,Brys Reginald²,De Vos Steve²^ORCID,Andrews Martin²,Jimenez Juan-Miguel²,Amantini David¹,Desroy Nicolas¹^ORCID

Affiliation:

1. Galapagos SASU, 93230 Romainville, France

2. Galapagos NV, 2800 Mechelen, Belgium

Funder

Gal?pagos

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c02246

Reference46 articles.

1. Nuts and bolts of the salt-inducible kinases (SIKs)

2. Cloning of a novel kinase (SIK) of the SNF1/AMPK family from high salt diet-treated rat adrenal1

3. Salt-Inducible Kinases: Physiology, Regulation by cAMP, and Therapeutic Potential

4. Small-molecule screening identifies inhibition of salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cells

5. SIK inhibition in human myeloid cells modulates TLR and IL-1R signaling and induces an anti-inflammatory phenotype

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Manual Therapy Improves Fibromyalgia Symptoms by Downregulating SIK1;International Journal of Molecular Sciences;2024-09-01

2. Understanding the roles of salt-inducible kinases in cardiometabolic disease;Frontiers in Physiology;2024-07-16